- Home
- TJGC vs CUE Comparison
TJGC vs CUE Comparison
Compare TJGC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | CUE |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 17.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TJGC | CUE |
|---|---|---|
| Price | $1.08 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 222.7K | ★ 19.4M |
| Earning Date | 08-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.49 | $0.17 |
| 52 Week High | $1.55 | $1.03 |
Technical Indicators
Market Signals| Indicator | TJGC | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 73.60 | 72.18 |
| Support Level | $1.01 | $0.24 |
| Resistance Level | $1.17 | $0.66 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 99.27 | 70.92 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.